Fig. 3: Treatment with lanabecestat in the AMARANTH trial decreases significantly β-Amyloid load for both the slow and rapid progressive individuals. | Nature Communications

Fig. 3: Treatment with lanabecestat in the AMARANTH trial decreases significantly β-Amyloid load for both the slow and rapid progressive individuals.

From: AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial

Fig. 3

A Mean β-Amyloid levels over time for Slow, Rapid, and All Progressive individuals (sample size: Supplementary Table S2) in the placebo (gray dashed), lanabecestat 20 mg (blue), and lanabecestat 50 mg (purple). Error bars indicate the standard error of the mean across individuals (SEM). B. Box plots of change in β-Amyloid levels (week 104 minus week1) for Slow, Rapid, and All Progressive (sample size: Supplementary Table S2). Black lines in the box plots indicate the median for placebo (gray), lanabecestat 20 mg (blue), and lanabecestat 50 mg (purple), the solid black box represents the 25th to 75th percentile, the black vertical lines represent the range of the data, and black circles indicate outliers. Asterisks indicate significant differences between treatment groups and placebo. Source data are provided as a Source Data file.

Back to article page